~~<i id='0BE7CA368A'><strike id='0BE7CA368A'><tt id='0BE7CA368A'><pre id='0BE7CA368A'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：hotspot 2025-09-27 10:55:55 Page View：5

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Problems with a popular proposal to regulate AI in health care
Next article： Hollywood unions extend contract negotiations for actors

comprehensive

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

Global cancer cases to surge 77% by 2050, WHO report says

MassGeneralCancerCenterThepredictionisdire:Cancercasesaroundtheworldareexpectedtosurge77%by2050,anew

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Pope Francis asks Church to identify 21st

PopeFranciswavesashearrivesfortheAngelusnoonprayerfromthewindowofhisstudiooverlookingSt.Peter'sSquar